aidsmap news story
Developing high blood pressure doubled the risk of experiencing a cardiovascular event, such as a stroke or heart attack, in the REPRIEVE study of statin treatment in people with HIV, and being assigned to pitavastatin significantly reduced the risk of developing high blood pressure, study investigators reported at CROI 2026.
The REPRIEVE study tested the effect of a daily dose of pitavastatin on the incidence of major cardiovascular events, such as stroke and heart attack, in people with HIV who had a low-to-moderate predicted risk of these serious events at study entry.
At CROI 2026, Dr Esteban Martinez of Barcelona’s Hospital Clinic presented the results of a secondary analysis looking at the impact of pitavastatin treatment on the incidence of new-onset hypertension during the REPRIEVE study. The analysis also looked at the relationship between developing high blood pressure during the study and subsequent cardiovascular events during the follow-up period.
Read the full news story here.
View all aidsmap reports from CROI 2026
SEE ALSO:
View all AJMC reports from CROI 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.